{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:22:42Z","timestamp":1787847762509,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) is an astrocytopathy with a predilection for the optic nerve, spinal cord, and brainstem. In this ambispective study, we evaluate clinical characteristics, responses to therapy, and disability outcomes in patients with NMOSD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients diagnosed as NMOSD and following up for at least 1 year at a tertiary care center in India were recruited. Patient data were collected ambispectively from January 2012 until December 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 106 patients (29M\/77F) with NMOSD were evaluated. The mean age of onset was 29 (\u00b111.6) years. About 77 patients (72.64%) were positive for the AQP4 antibody. Age of onset was higher for those presenting with an opticospinal syndrome (34.2 years) as compared to either isolated longitudinally extensive transverse myelitis (LETM) (30 years) or optic neuritis (ON) (25.3 years). The most common syndrome at onset was LETM in 57 patients (53.77%) followed by ON in 31 patients (29.24%). Azathioprine was the most common immunotherapy (83.96%) prescribed followed by rituximab (7.54%) and mycophenolate mofetil (1.88%). There was a significant decrease in the number of relapses post-azathioprine (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). Out of 67 patients with ON, 21 (31.34%) had complete recovery while 17 (25.37%) patients had a severe deficit at a 3-month follow-up. Out of 92 patients with a motor deficit, 49 (53.26%) patients had a partial motor deficit at a 6-month follow-up. The severe visual deficit at baseline and female gender predicted poor visual and motor recovery, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This is the largest descriptive study on patients with NMOSD from India. Relapse rates were similar irrespective of the clinical presentation, age, gender, and disease course. Treatment with immunosuppressive treatment significantly affected the disease course.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_334_20","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T05:54:53Z","timestamp":1609912493000},"page":"186-191","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Features, Gender Differences, Disease Course, and Outcome in Neuromyelitis Optica Spectrum Disorder"],"prefix":"10.4103","volume":"24","author":[{"given":"Nishita","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Bali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Sreenivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M V","family":"Padma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Leve","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20240828","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"R2-14-20240828","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"R3-14-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R4-14-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R5-14-20240828","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/jnnp-2017-317566","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorders","volume":"89","author":"Mori","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R6-14-20240828","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.msard.2019.01.032","article-title":"Clinical, neuroimaging and therapeutic response in AQP4-positive NMO patients from India","volume":"30","author":"Netravathi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"R7-14-20240828","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.0b013e3181d31e35","article-title":"Neuromyelitis optica in France: A multicenter study of 125 patients","volume":"74","author":"Collongues","year":"2010","journal-title":"Neurology"},{"key":"R8-14-20240828","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00415-009-5171-x","article-title":"Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution","volume":"256","author":"Bizzoco","year":"2009","journal-title":"J Neurol"},{"key":"R9-14-20240828","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain J Neurol"},{"key":"R10-14-20240828","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s00415-010-5780-4","article-title":"Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients","volume":"258","author":"Akman-Demir","year":"2011","journal-title":"J Neurol"},{"key":"R11-14-20240828","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/1352458509353651","article-title":"Recurrent neuromyelitis optica in Brazilian patients: Clinical, immunological, and neuroimaging characteristics","volume":"16","author":"Adoni","year":"2010","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"R12-14-20240828","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus","volume":"3","author":"Sep\u00falveda","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"R13-14-20240828","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1212\/WNL.0b013e318230a17d","article-title":"Age and disability accumulation in multiple sclerosis","volume":"77","author":"Scalfari","year":"2011","journal-title":"Neurology"},{"key":"R14-14-20240828","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00415-008-0781-2","article-title":"Characteristics of Devic's disease (neuromyelitis optica) in Mexico","volume":"255","author":"Rivera","year":"2008","journal-title":"J Neurol"},{"key":"R15-14-20240828","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1352458508101935","article-title":"Neuromyelitis optica in Brazil: A study on clinical and prognostic factors","volume":"15","author":"Bichuetti","year":"2009","journal-title":"Mult Scler J"},{"key":"R16-14-20240828","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1177\/1352458511403958","article-title":"Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders","volume":"17","author":"Jarius","year":"2011","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"key":"R17-14-20240828","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.msard.2017.06.008","article-title":"Gender differences among Chinese patients with neuromyelitis optica spectrum disorders","volume":"17","author":"Sun","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"R18-14-20240828","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: Results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","journal-title":"J Neurol Sci"},{"key":"R19-14-20240828","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","article-title":"NMO-IgG predicts the outcome of recurrent optic neuritis","volume":"70","author":"Matiello","year":"2008","journal-title":"Neurology"},{"key":"R20-14-20240828","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ana.20770","article-title":"Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis","volume":"59","author":"Weinshenker","year":"2006","journal-title":"Ann Neurol"},{"key":"R21-14-20240828","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: A meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol"},{"key":"R22-14-20240828","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaneurol.2016.5933","article-title":"Rituximab in neuromyelitis optica spectrum disorders: Why not as first-line therapy","volume":"74","author":"Kim","year":"2017","journal-title":"JAMA Neurol"},{"key":"R23-14-20240828","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"R24-14-20240828","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1001\/archneur.65.5.629","article-title":"Aquaporin-4 autoantibodies in a paraneoplastic context","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"R25-14-20240828","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_334_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:36:21Z","timestamp":1787844981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.AIAN_334_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_334_20","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}